Over the last four years, there have been substantial changes in IPOs in the software world. Firms tend to wait longer to go public, while raising larger late-stage private rounds and eventually experiencing high public market valuations. We wanted to take a closer look at this trend with the objective to gain some insights into current practices. To that end, we looked at the results of 58 software companies that have gone public in the US since 2013.
Startups succeed because of their founders, but what makes a successful founder? We wanted to find out what backgrounds founders were bringing to their companies, so we undertook research to determine the educational backgrounds of founders of over 300 technology companies.
We’ve updated the Narwhal List and released a new report for 2019. Canada’s tech community continues to make progress but we haven’t created a new Unicorn since 2015. The technology sector has doubled the number of companies that are on track to become Unicorns but the healthcare sector continues its slow decline.
This report is the result of a forum held in February 2018 on the challenges that companies in the physical technologies face in commercialization. Forum participants had a robust discussion around the challenges outlined in our previous report on Physical Technologies and identified a number of other commercialization hurdles, including weak institutional support, knowledge and information gaps, lack of prototyping facilities and short run manufacturing, among other issues.
Effective intergovernmental coordination in research and innovation funding has been a persistent challenge in Canada. The dizzying mix of initiatives for research and innovation at both levels has also contributed to the coordination challenge, which has resulted in a patchwork of programs and co-matching requirements. Researchers and innovators are left to navigate a complex system of supports, seeking opportunities to help cover R&D costs.
This report examines the shape of the health technology industry in Canada with a focus on three specific questions: Does Canada actually have a problem with health tech commercialization? If so, how extensive is that problem? And what is causing it?